SEP 13, 2017 6:00 AM PDT

Next-generation probiotics targeting C. difficile infection

Speaker
  • Instructor, Pathology & Immunology, Baylor College of Medicine
    Biography
      Dr. Spinler is an experienced classical microbiologist with extensive training in bacterial genetics and genomics currently serving as faculty at Baylor College of Medicine in the Texas Children's Microbiome Center. Her expertise in developing mutagenesis systems for investigations of gram-positive bacteria which has contributed to recent successes with genetics of probiotics; particularly in the area of antimicrobial production by Lactobacillus reuteri. Current research efforts combine comparative and functional genomics strategies with animal models and microbiome research to understand how individual probiotic organisms beneficially impact the larger microbiome community of the gastrointestinal tract and how these interactions protect against antibiotic-associated disease. Specifically, her research is aimed at developing adjunct probiotic therapies targeting C. difficile infection. As a probiotic researcher in a hospital-based microbiome center, Dr. Spinler has the benefit of combining her expertise with clinically relevant microbiome studies which has tremendous potential to impact our basic understanding of mechanisms of bacterial resistance and create new translational opportunities combatting antimicrobial resistance.

    Abstract

    Adjunct probiotic therapy has the potential to decrease Clostridium difficile disease incidence and severity. After screening several potential probiotic bacteria for intrinsic resistance to C. difficile antibiotics (vancomycin, metronidazole and fidaxomicin), we determined that L. reuteri strains are ideal adjunct therapy candidates. We evaluated the ability of reuterin - a secondary metabolite produced by specific strains of L. reuteri during fermentation of the prodrug glycerol - to inhibit C. difficile growth in vitro.  We found that levels of reuterin produced by L. reuteri 17938 were more potent than vancomycin in inhibiting C. difficile growth. Using human fecal microbiota bioreactors, we showed that co-delivery of L. reuteri with glycerol is effective against C. difficile colonization of a complex-microbial community, whereas treatment with either glycerol or L. reuteri alone was ineffective.  Co-delivery of L. reuteri and glycerol changed microbial community profiles and associated metabolites consistent with glycerol fermentation and reuterin production.  Ex vivo studies showed that this combination therapy resulted in lower C. difficile burden and toxicity in stool and that this was dependent upon reuterin production. Taken together, prodrug-based adjunct therapy with probiotic L. reuteri is a viable option for preventative treatment of C. difficile infection.  

     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    SEP 13, 2017 6:00 AM PDT

    Next-generation probiotics targeting C. difficile infection


    Specialty

    Earth Sciences

    Molecular Biology

    Earth Science

    University

    Pharmacology

    Manufacturing

    Ecology

    Clinical Chemistry

    Research

    Quality Control/assurance

    Microbiology

    Infectious Disease

    Lab Automation

    Health

    Research And Development

    Geography

    North America17%

    Asia17%

    South America17%

    Registration Source

    Website Visitors100%

    Job Title

    QC/QA33%

    Medical Laboratory Technician33%

    Chemist33%

    Organization

    Manufacturer - Other17%

    Academic Institution17%

    Other17%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more